The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures?This article is co-published with permission in Allergy and the World Allergy Organization Journal.

[1]  M. Levi,et al.  COVID-19 vaccination and the risk of swellings in patients with hereditary angioedema , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[2]  G. Karakaya,et al.  Effect of COVID-19 on hereditary angioedema activity and quality of life. , 2021, Allergy and asthma proceedings.

[3]  J. Bernstein,et al.  Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study , 2021, Allergy.

[4]  A. Nicolas,et al.  [Impact of disease on daily activities, emotions and quality of life of patients with hereditary angioedema]. , 2021, La Revue de medecine interne.

[5]  M. Maurer,et al.  Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema☆ , 2021, The World Allergy Organization journal.

[6]  M. Manning,et al.  Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies. , 2021, Allergy and asthma proceedings.

[7]  H. Iocca,et al.  Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study , 2021, Clinical and translational allergy.

[8]  S. Waserman,et al.  How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both. , 2021, The journal of allergy and clinical immunology. In practice.

[9]  J. Bernstein,et al.  Consensus on treatment goals in hereditary angioedema: a global Delphi initiative. , 2021, The Journal of allergy and clinical immunology.

[10]  R. Krüger,et al.  Lanadelumab efficacy, safety, and injection interval extension in HAE - a real life study. , 2021, The journal of allergy and clinical immunology. In practice.

[11]  W. Aberer,et al.  Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema , 2021, Clinical Reviews in Allergy & Immunology.

[12]  C. Maas,et al.  Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema , 2021, Clinical Reviews in Allergy & Immunology.

[13]  D. Mungan,et al.  Psychiatric and Clinical Characteristics of Hereditary Angioedema Patients Who Experienced Attacks during COVID-19. , 2021, Journal of investigational allergology & clinical immunology.

[14]  M. Mesquita,et al.  Acute urticaria in children: from pediatric emergency department to allergology consultation at a central hospital. , 2021, European annals of allergy and clinical immunology.

[15]  T. Craig,et al.  Short-term prophylaxis for children and adolescents with hereditary angioedema. , 2021, Allergy and asthma proceedings.

[16]  J. Simon,et al.  Prophylactic Treatment in Hereditary Angioedema Is Associated with Reduced Anxiety in Patients in Leipzig, Germany , 2021, International Archives of Allergy and Immunology.

[17]  K. Weller,et al.  Patient-reported Outcome Measures for Angioedema: A Literature Review , 2021, Acta dermato-venereologica.

[18]  T. Craig,et al.  Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report , 2021, Allergy, Asthma & Clinical Immunology.

[19]  J. Bernstein,et al.  Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). , 2021, The journal of allergy and clinical immunology. In practice.

[20]  M. Cicardi,et al.  Hereditary angioedema due to C1 inhibitor deficiency in Belarus: epidemiology, access to diagnosis and seven novel mutations in SERPING1 gene , 2021, Clinical and Molecular Allergy.

[21]  L. Arruda,et al.  Hereditary angioedema: how to approach it at the emergency department? , 2021, Einstein.

[22]  J. Bernstein,et al.  Recognition, Evaluation, and Management of Pediatric Hereditary Angioedema. , 2021, Pediatric emergency care.

[23]  D. Launay,et al.  COVID‐19 as a trigger of acute attacks in people with hereditary angioedema , 2021, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  J. Pesquero,et al.  Unnecessary Abdominal Surgeries in Attacks of Hereditary Angioedema with Normal C1 Inhibitor , 2021, Clinical Reviews in Allergy & Immunology.

[25]  H. Farkas,et al.  How Angioedema Quality of Life Questionnaire Can Help Physicians in Treating C1-Inhibitor Deficiency Patients? , 2021, Clinical Reviews in Allergy & Immunology.

[26]  E. Aygören‐Pürsün,et al.  Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey , 2021, Orphanet Journal of Rare Diseases.

[27]  P. Keith,et al.  Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study , 2021, Orphanet Journal of Rare Diseases.

[28]  B. Zuraw,et al.  Assessing the cost and quality-of-life impact of on-demand- only medications for adults with hereditary angioedema. , 2021, Allergy and asthma proceedings.

[29]  E. Aygören‐Pürsün,et al.  Subcutaneous C1‐Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1‐INH‐HAE , 2021, Clinical case reports.

[30]  R. Somech,et al.  New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA) , 2021, Clinical Reviews in Allergy & Immunology.

[31]  M. Maurer,et al.  Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell–Mediated Angioedema , 2021, Clinical Reviews in Allergy & Immunology.

[32]  A. Reshef,et al.  The Enigma of Prodromes in Hereditary Angioedema (HAE) , 2021, Clinical Reviews in Allergy & Immunology.

[33]  A. Banerji,et al.  Optimal Management of Hereditary Angioedema: Shared Decision-Making , 2021, Journal of asthma and allergy.

[34]  F. Minafra,et al.  The Challenges in the Follow-Up and Treatment of Brazilian Children with Hereditary Angioedema , 2021, International Archives of Allergy and Immunology.

[35]  Britta S. Möhl,et al.  Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation. , 2021, The Journal of allergy and clinical immunology.

[36]  Darjan Kardum,et al.  Successful treatment with Cinryze® replacement therapy of a pregnant patient with hereditary angioedema: a case report , 2021, Journal of Medical Case Reports.

[37]  P. Kralickova,et al.  Acquired Angioedema with C1 Inhibitor Deficiency: Occurrence, Clinical Features, and Management: A Nationwide Retrospective Study in the Czech Republic Patients , 2021, International Archives of Allergy and Immunology.

[38]  J. Bernstein,et al.  A robust multiplexed assay to quantify C1-inhibitor, C1q, and C4 proteins for in vitro diagnosis of hereditary angioedema from dried blood spot. , 2020, Journal of pharmaceutical and biomedical analysis.

[39]  J. Bernstein,et al.  Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies. , 2020, Allergy and asthma proceedings.

[40]  A. Emelyanov,et al.  [Diagnosis and treatment of hereditary angioedema with normal C1-inhibitor level]. , 2020, Terapevticheskii arkhiv.

[41]  S. Patro,et al.  Acute Presentation of Undiagnosed Hereditary Angioedema of the Larynx: Averting Death. , 2020, Turkish archives of otorhinolaryngology.

[42]  W. Lumry,et al.  Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study , 2020, Allergy.

[43]  E. Goudouris,et al.  COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[44]  Yusuke Suzuki,et al.  Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial , 2020, Allergy.

[45]  H. Farkas,et al.  A follow‐up survey of patients with acquired angioedema due to C1‐inhibitor deficiency , 2020, Journal of internal medicine.

[46]  J. Pines,et al.  Recognition and Differential Diagnosis of Hereditary Angioedema in the Emergency Department. , 2020, The Journal of emergency medicine.

[47]  T. Craig.  Triggers and short-term prophylaxis in patients with hereditary angioedema. , 2020, Allergy and asthma proceedings.

[48]  N. Maina,et al.  Hereditary angioedema: Comprehensive management plans and patient support. , 2020, Allergy and asthma proceedings.

[49]  W. Lumry,et al.  Hereditary angioedema: Epidemiology and burden of disease. , 2020, Allergy and asthma proceedings.

[50]  D. Johnston,et al.  Hereditary angioedema: Special considerations in children. , 2020, Allergy and asthma proceedings.

[51]  J. Bernstein,et al.  Definition and classification of hereditary angioedema. , 2020, Allergy and asthma proceedings.

[52]  H. Farkas,et al.  Deciphering the Genetics of Primary Angioedema with Normal Levels of C1 Inhibitor , 2020, Journal of clinical medicine.

[53]  William H. Yang,et al.  Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.

[54]  T. Machnig,et al.  Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence , 2020, Orphanet Journal of Rare Diseases.

[55]  M. Wigand,et al.  Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience. , 2020, Journal of drugs in dermatology : JDD.

[56]  H. Farkas,et al.  The importance of complement testing in acquired angioedema related to angiotensin-converting enzyme inhibitors. , 2020, The journal of allergy and clinical immunology. In practice.

[57]  J. Bernstein,et al.  US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. , 2020, The journal of allergy and clinical immunology. In practice.

[58]  M. Kowalski,et al.  Angioedema. Interdisciplinary diagnostic and therapeutic recommendations of the Polish Dermatological Society (PTD) and Polish Society of Allergology (PTA) , 2020, Postepy dermatologii i alergologii.

[59]  S. Fayyaz,et al.  Novel Use of Fresh Frozen Plasma in Treating Hereditary Angioedema: A Success Story From Pakistan , 2020, Cureus.

[60]  P. Jeandel,et al.  [Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment]. , 2020, La Revue de medecine interne.

[61]  M. Margaglione,et al.  A myoferlin gain‐of‐function variant associates with a new type of hereditary angioedema , 2020, Allergy.

[62]  R. Krüger,et al.  Hereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[63]  Kevin J. Burnham,et al.  Thromboembolic Risk of C1 Esterase Inhibitors: A Systematic Review on Current Evidence , 2020, Expert review of clinical pharmacology.

[64]  J. Bernstein,et al.  Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks , 2020, Allergy.

[65]  Praveen Sankrithi,et al.  Pregnancy-Induced Exacerbation of Hereditary Angioedema in a Multiparous Caucasian Female , 2020, Cureus.

[66]  J. Poza Cordón,et al.  Ultrasound findings in an abdominal crisis of a patient with hereditary angioedema. , 2020, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[67]  Todor A Popov,et al.  Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence , 2020, Allergy.

[68]  M. Riedl,et al.  Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. , 2020, The journal of allergy and clinical immunology. In practice.

[69]  C. Katelaris.  Self-Management Plans in Patients with Hereditary Angioedema: Strategies, Outcomes and Integration into Clinical Care , 2020, Journal of asthma and allergy.

[70]  G. Porebski,et al.  Life-threatening laryngeal attacks in hereditary angioedema patients. , 2020, Otolaryngologia polska = The Polish otolaryngology.

[71]  T. Zuberbier,et al.  Validation of the Angioedema Control Test (AECT) - a patient reported outcome instrument for assessing angioedema control. , 2020, The journal of allergy and clinical immunology. In practice.

[72]  T. Brown,et al.  Patient-reported burden of hereditary angioedema: findings from a US patient survey. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[73]  T. Machnig,et al.  Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene , 2020, Orphanet Journal of Rare Diseases.

[74]  L. Bouillet,et al.  Update on bradykinin-mediated angioedema in 2020. , 2020, Therapie.

[75]  B. Zuraw,et al.  Contact System Activation During Erythema Marginatum In Hereditary Angioedema. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[76]  N. Prior,et al.  HAE-AS, a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. , 2020, Journal of investigational allergology & clinical immunology.

[77]  Moshe Y. Vardi,et al.  [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY]. , 2020, Arerugi = [Allergy].

[78]  T. Hoffmann,et al.  Successful Long-Term Prophylactic Treatment With Subcutaneous C1 Esterase Inhibitor in a Patient With Hereditary Angioedema , 2020, Journal of pharmacy practice.

[79]  S. Cichon,et al.  International consensus on the use of genetics in the management of hereditary angioedema. , 2020, The journal of allergy and clinical immunology. In practice.

[80]  R. Shapiro,et al.  Recombinant Human C1 Esterase Inhibitor as Short-Term Prophylaxis in Patients With Hereditary Angioedema. , 2020, The journal of allergy and clinical immunology. In practice.

[81]  M. López-Trascasa,et al.  SERPING1 mutation update: Mutation spectrum and C1 Inhibitor phenotypes , 2019, Human mutation.

[82]  M. Margaglione,et al.  Impaired control of the contact system in hereditary angioedema with normal C1‐inhibitor , 2019, Allergy.

[83]  T. Zuberbier,et al.  Development of the Angioedema Control Test—A patient‐reported outcome measure that assesses disease control in patients with recurrent angioedema , 2019, Allergy.

[84]  T. Simon,et al.  Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema. , 2019, Allergy and asthma proceedings.

[85]  T. Zuberbier,et al.  Diagnosis and treatment of chronic inducible urticaria , 2019, Allergy.

[86]  P. Keith,et al.  The International/Canadian Hereditary Angioedema Guideline , 2019, Allergy, Asthma & Clinical Immunology.

[87]  J. Bernstein,et al.  Safety of Recombinant Human C1 Esterase Inhibitor for Hereditary Angioedema Attacks During Pregnancy. , 2019, The journal of allergy and clinical immunology. In practice.

[88]  M. Maurer,et al.  Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients , 2019, BioMed research international.

[89]  M. Maurer,et al.  Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change , 2019, Health and Quality of Life Outcomes.

[90]  L. Brussino,et al.  Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research , 2019, Drugs in context.

[91]  M. Levin,et al.  Fresh frozen plasma for on-demand hereditary angioedema treatment in South Africa and Iran , 2019, The World Allergy Organization journal.

[92]  T. Machnig,et al.  Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study , 2019, Allergy, Asthma & Clinical Immunology.

[93]  C. Maas,et al.  Hereditary Angioedema: Insights into inflammation and allergy. , 2019, Molecular immunology.

[94]  B. Long,et al.  Evaluation and Management of Angioedema in the Emergency Department , 2019, The western journal of emergency medicine.

[95]  S. Valle,et al.  Hereditary angioedema: Screening of first-degree blood relatives and earlier diagnosis. , 2019, Allergy and asthma proceedings.

[96]  William H. Yang,et al.  Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. , 2019, The journal of allergy and clinical immunology. In practice.

[97]  I. Braenne,et al.  Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N‐terminal cleavage site of bradykinin , 2019, Allergy.

[98]  H. Farkas,et al.  Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[99]  William H. Yang,et al.  Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study. , 2019, The journal of allergy and clinical immunology. In practice.

[100]  Moshe Y. Vardi,et al.  A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[101]  Ş. Pırıldar,et al.  The impact of hereditary angioedema on quality of life and family planning decisions , 2019, International journal of psychiatry in medicine.

[102]  K. Bork,et al.  Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate , 2019, Orphanet Journal of Rare Diseases.

[103]  T. Machnig,et al.  Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks , 2019, Allergy, Asthma & Clinical Immunology.

[104]  G. Hayman,et al.  Chronic spontaneous urticaria and angioedema requiring treatment with omalizumab in a patient with hereditary angioedema. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[105]  T. Horiuchi,et al.  A novel C1 inhibitor gene mutation in a family with hereditary angioedema: Use of genetic analysis to facilitate early diagnosis. , 2019, Allergology international : official journal of the Japanese Society of Allergology.

[106]  W. Lumry,et al.  Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[107]  M. Maurer,et al.  Klassifikation und Pathophysiologie von Angioödemen , 2018, Der Hautarzt.

[108]  William H. Yang,et al.  Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.

[109]  Gabriella Gábos,et al.  Consequences of Misdiagnosed and Mismanaged Hereditary Angioedema Laryngeal Attacks: An Overview of Cases from the Romanian Registry , 2018, Case reports in emergency medicine.

[110]  M. Cicardi,et al.  Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema , 2018, Expert review of clinical immunology.

[111]  P. Keith,et al.  Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. , 2018, The journal of allergy and clinical immunology. In practice.

[112]  M. Triggiani,et al.  Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema , 2018, The New England journal of medicine.

[113]  C. Maas,et al.  Hereditary angioedema: the plasma contact system out of control , 2018, Journal of thrombosis and haemostasis : JTH.

[114]  M. Cicardi,et al.  Angioedema Due to Bradykinin Dysregulation. , 2018, The journal of allergy and clinical immunology. In practice.

[115]  T. Zuberbier,et al.  The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria , 2018, Allergy.

[116]  M. Triggiani,et al.  Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study , 2018, Allergy.

[117]  M. Riedl,et al.  Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema , 2018, Clinical Reviews in Allergy & Immunology.

[118]  P. Schmid‐Grendelmeier,et al.  Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema , 2018, Orphanet Journal of Rare Diseases.

[119]  H. Farkas,et al.  Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years , 2018, Expert review of clinical immunology.

[120]  A. Maetzel,et al.  Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies , 2018, Orphanet Journal of Rare Diseases.

[121]  A. Zanichelli,et al.  Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study , 2018, Orphanet Journal of Rare Diseases.

[122]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[123]  H. Longhurst.  Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus , 2018, Front. Med..

[124]  I. Braenne,et al.  Hereditary angioedema with a mutation in the plasminogen gene , 2018, Allergy.

[125]  T. Nakayama,et al.  Comparison of the Frequency of Angioedema Attack, before and during Pregnancy, in a Patient with Type I Hereditary Angioedema , 2017, Internal medicine.

[126]  M. Margaglione,et al.  Mutation of the angiopoietin‐1 gene (ANGPT1) associates with a new type of hereditary angioedema , 2017, The Journal of allergy and clinical immunology.

[127]  T. Hoffmann,et al.  [The ulm emergency algorithm for the acute treatment of drug-induced, bradykinin-mediated angioedema]. , 2018, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

[128]  G. Mortier,et al.  Hereditary angioedema in 2 sisters due to paternal gonadal mosaicism. , 2018, The journal of allergy and clinical immunology. In practice.

[129]  P. Busse,et al.  Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema , 2017, Front. Med..

[130]  Jimmy Gonzalez,et al.  Angiotensin‐converting enzyme inhibitor–induced angioedema: A review of the literature , 2017, Journal of clinical hypertension.

[131]  C. Wahlgren,et al.  Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden. , 2017, Allergy and asthma proceedings.

[132]  W. Aberer,et al.  Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.

[133]  T. Kelbel,et al.  Multiple doses of icatibant used during pregnancy , 2017, Allergy & rhinology.

[134]  C. Koch,et al.  Complement factor C4 activation in patients with hereditary angioedema. , 2017, Clinical biochemistry.

[135]  M. Cicardi,et al.  Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency. , 2017, The journal of allergy and clinical immunology. In practice.

[136]  S. Betschel,et al.  The Clinical Evaluation of Angioedema. , 2017, Immunology and allergy clinics of North America.

[137]  N. Prior,et al.  Burden of Illness and Quality-of-Life Measures in Angioedema Conditions. , 2017, Immunology and allergy clinics of North America.

[138]  C. Maas,et al.  Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment. , 2017, Immunology and allergy clinics of North America.

[139]  W. Aberer,et al.  Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey , 2017, Allergy, Asthma & Clinical Immunology.

[140]  J. Edelman,et al.  Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema. , 2017, Allergy and asthma proceedings.

[141]  William H. Yang,et al.  Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.

[142]  D. Supina,et al.  Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. , 2017, Allergy and asthma proceedings.

[143]  C. Fagerberg,et al.  Clinical characteristics and real-life diagnostic approaches in all Danish children with hereditary angioedema , 2017, Orphanet Journal of Rare Diseases.

[144]  T. Machnig,et al.  Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema , 2017, Allergy & rhinology.

[145]  B. Floccard,et al.  Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort , 2017, European Journal of Dermatology.

[146]  A. Forrest,et al.  Hereditary angioedema: death after a dental extraction. , 2017, Australian dental journal.

[147]  R. Lockey,et al.  Inhibiting plasma kallikrein for hereditary angioedema prophylaxis , 2017 .

[148]  C. von Buchwald,et al.  Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema , 2017, International journal of otolaryngology.

[149]  K. Bork,et al.  Treatment for hereditary angioedema with normal C1‐INH and specific mutations in the F12 gene (HAE‐FXII) , 2017, Allergy.

[150]  M. Triggiani,et al.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency , 2016, Allergy.

[151]  J. Bernstein,et al.  Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[152]  H. Farkas,et al.  Bacteriuria increases the risk of edematous attacks in hereditary angioedema with C1‐inhibitor deficiency , 2016, Allergy.

[153]  T. Renné,et al.  Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. , 2016, The Journal of allergy and clinical immunology.

[154]  J. Bernstein,et al.  Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2016, Pediatrics.

[155]  M. Triggiani,et al.  High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study , 2016, Orphanet Journal of Rare Diseases.

[156]  Huamin H. Li.  Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance , 2016, Patient preference and adherence.

[157]  J. Bernstein,et al.  Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey , 2016, Allergy & rhinology.

[158]  B. Zuraw,et al.  Tolerability and Effectiveness of 17-α-Alkylated Androgen Therapy for Hereditary Angioedema: A Re-examination. , 2016, The journal of allergy and clinical immunology. In practice.

[159]  W. Kreuz,et al.  Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat. , 2016, The Journal of allergy and clinical immunology.

[160]  J. Bernstein,et al.  Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. , 2016, The journal of allergy and clinical immunology. In practice.

[161]  B. Zuraw,et al.  Pediatric Hereditary Angioedema , 2016, Clinical pediatrics.

[162]  V. Leblond,et al.  A nationwide study of acquired C1-inhibitor deficiency in France , 2016, Medicine.

[163]  M. Maurer,et al.  Effect of omalizumab on angioedema in H1‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trial , 2016, Allergy.

[164]  P. Martus,et al.  The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important difference , 2016, Allergy. European Journal of Allergy and Clinical Immunology.

[165]  H. Farkas,et al.  First report of icatibant treatment in a pregnant patient with hereditary angioedema , 2016, The journal of obstetrics and gynaecology research.

[166]  B. Zuraw,et al.  HAE Pathophysiology and Underlying Mechanisms , 2016, Clinical Reviews in Allergy & Immunology.

[167]  M. Kidon,et al.  The Story of Angioedema: from Quincke to Bradykinin , 2016, Clinical Reviews in Allergy & Immunology.

[168]  A. Kaplan,et al.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent , 2016, Clinical Reviews in Allergy & Immunology.

[169]  M. Magerl,et al.  An analysis of the teaching of intravenous self‐administration in patients with hereditary angio‐oedema , 2016, Clinical and experimental dermatology.

[170]  H. Farkas.  Icatibant as acute treatment for hereditary angioedema in adults , 2016, Expert review of clinical pharmacology.

[171]  H. Farkas,et al.  “Nuts and Bolts” of Laboratory Evaluation of Angioedema , 2016, Clinical Reviews in Allergy & Immunology.

[172]  T. Renné,et al.  Urticaria as a Presenting Prodromal Manifestation of Attacks of Hereditary Angioedema. , 2016, Acta dermato-venereologica.

[173]  W. Aberer,et al.  Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. , 2016, The journal of allergy and clinical immunology. In practice.

[174]  L. Aagaard,et al.  Real-life experience with long-term prophylactic C1 inhibitor concentrate treatment of patients with hereditary angioedema: Effectiveness and cost. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[175]  M. Speletas,et al.  Genetics of Hereditary Angioedema Revisited , 2016, Clinical Reviews in Allergy & Immunology.

[176]  T. Machnig,et al.  Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency. , 2016, The Journal of emergency medicine.

[177]  M. Magerl,et al.  Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[178]  H. Farkas,et al.  Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. , 2016, Allergy and asthma proceedings.

[179]  R. Krüger,et al.  Daily subcutaneous administration of human C1 inhibitor in a child with hereditary angioedema type 1 , 2016, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[180]  J. Greve,et al.  Prophylaxe beim hereditären Angioödem (HAE) mit C1‐Inhibitormangel , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[181]  A. Bygum,et al.  Urticaria and Prodromal Symptoms Including Erythema Marginatum in Danish Patients with Hereditary Angioedema. , 2016, Acta dermato-venereologica.

[182]  H. Farkas,et al.  The effect of long-term danazol treatment on haematological parameters in hereditary angioedema , 2016, Orphanet Journal of Rare Diseases.

[183]  H. Farkas,et al.  Erythema Marginatum as an Early Symptom of Hereditary Angioedema: Case Report of 2 Newborns , 2016, Pediatrics.

[184]  H. Longhurst,et al.  Optimizing hereditary angioedema management through tailored treatment approaches , 2016, Expert review of clinical immunology.

[185]  R. Krüger,et al.  Subcutaneous self‐injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio‐oedema , 2016, Clinical and experimental dermatology.

[186]  W. Aberer,et al.  Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. , 2016, Journal of investigational allergology & clinical immunology.

[187]  C. Marcos,et al.  Management of Pregnancy and Delivery in Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency. , 2016, Journal of investigational allergology & clinical immunology.

[188]  G. Casazza,et al.  Efficacy of on‐demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency , 2015, Allergy.

[189]  W. Lumry,et al.  Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[190]  P. Staubach,et al.  High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema , 2015, Skin Pharmacology and Physiology.

[191]  G. Kojda,et al.  Angioedema induced by cardiovascular drugs: new players join old friends , 2015, Allergy.

[192]  W. Aberer,et al.  Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey. , 2015, Allergy and asthma proceedings.

[193]  J. Bernstein,et al.  Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate , 2015, Allergy.

[194]  J. Bernstein,et al.  Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. , 2015, Immunotherapy.

[195]  W. Aberer,et al.  Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals , 2015, International Archives of Allergy and Immunology.

[196]  M. Riedl.  Recombinant Human C1 Esterase Inhibitor in the Management of Hereditary Angioedema , 2015, Clinical Drug Investigation.

[197]  M. Boubaya,et al.  Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[198]  M. Gompels,et al.  C1 inhibitor deficiency: 2014 United Kingdom consensus document , 2015, Clinical and experimental immunology.

[199]  Y. Benhamou,et al.  Icatibant in ACE-inhibitor-induced angioedema. , 2015, The New England journal of medicine.

[200]  S. Neri,et al.  Use of subcutaneous‐C1 INH for acute therapy and prophylaxis of a child with HAE , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[201]  A. Gompel,et al.  [Hereditary angiœdema treatments: Recommendations from the French national center for angiœdema (Bordeaux consensus 2014)]. , 2015, Presse medicale.

[202]  J. Bernstein,et al.  Current state of hereditary angioedema management: a patient survey. , 2015, Allergy and asthma proceedings.

[203]  Y. Makino,et al.  [Perioperative Management of a Patient with Hereditary Angioedema: A Case Report]. , 2015, Masui. The Japanese journal of anesthesiology.

[204]  M. Riedl.  Critical appraisal of androgen use in hereditary angioedema: a systematic review. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[205]  D. Launay,et al.  Traitements des angiœdèmes héréditaires : recommandations du centre de référence national des angiœdèmes (consensus 2014 de Bordeaux) , 2015 .

[206]  J. Biedenkapp,et al.  Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. , 2015, The journal of allergy and clinical immunology. In practice.

[207]  J. Bernstein,et al.  Facilitating home-based treatment of hereditary angioedema. , 2015, Allergy and asthma proceedings.

[208]  J. Bernstein,et al.  Before and after, the impact of available on-demand treatment for HAE. , 2015, Allergy and asthma proceedings.

[209]  T. Craig,et al.  Perioperative management for patients with hereditary angioedema , 2015, Allergy & rhinology.

[210]  M. Triggiani,et al.  A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy , 2015, Orphanet Journal of Rare Diseases.

[211]  A. Knulst,et al.  Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: a retrospective study , 2015, Clinical and Translational Allergy.

[212]  A. Tordai,et al.  Hereditary angioedema: molecular and clinical differences among European populations. , 2015, The Journal of allergy and clinical immunology.

[213]  G. Kojda,et al.  A randomized trial of icatibant in ACE-inhibitor-induced angioedema. , 2015, The New England journal of medicine.

[214]  M. López-Trascasa,et al.  Complement Study Versus CINH Gene Testing for the Diagnosis of Type I Hereditary Angioedema in Children , 2015, Journal of Clinical Immunology.

[215]  I. Boccon-Gibod.  Angioedèmes héréditaires : traitements et éducation thérapeutique , 2015 .

[216]  A. Zanichelli,et al.  Icatibant Exposure During Pregnancy in a Patient With Hereditary Angioedema. , 2015, Journal of investigational allergology & clinical immunology.

[217]  I. Boccon-Gibod.  [Hereditary angioedema: treatment and educational therapeutic program]. , 2015, Presse medicale.

[218]  J. Raoul,et al.  Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema , 2014, Case Reports in Oncology.

[219]  H. Farkas,et al.  Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema , 2014, Orphanet Journal of Rare Diseases.

[220]  K. Bauer,et al.  The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. , 2014, Allergy and asthma proceedings.

[221]  P. Keith,et al.  Canadian hereditary angioedema guideline , 2014, Allergy, Asthma & Clinical Immunology.

[222]  GiladOded,et al.  Outcome following tranexamic acid exposure during breastfeeding. , 2014 .

[223]  J. Biedenkapp,et al.  A phase 1 study investigating DX-2930 in healthy subjects. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[224]  A. Bygum,et al.  Hereditary Angioedema: Children Should be Considered for Training in Self‐Administration , 2014, Pediatric dermatology.

[225]  R. Cabañas,et al.  Management of hereditary angioedema in pregnant women: a review , 2014 .

[226]  W. Lumry,et al.  Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. , 2014, Allergy and asthma proceedings.

[227]  J. Bernstein,et al.  A cross-sectional questionnaire assessing patient and physician use of short-term prophylaxis for hereditary angioedema. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[228]  A. Bygum.  Hereditary angioedema - consequences of a new treatment paradigm in Denmark. , 2014, Acta dermato-venereologica.

[229]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[230]  T. Craig,et al.  Barriers to self-administered therapy for hereditary angioedema. , 2014, Allergy and asthma proceedings.

[231]  M. Triggiani,et al.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[232]  J. Sheikh,et al.  The diagnosis and management of acute and chronic urticaria: 2014 update. , 2014, The Journal of allergy and clinical immunology.

[233]  W. Kreuz,et al.  Characterization of prodromal symptoms in a large population of patients with hereditary angio‐oedema , 2014, Clinical and experimental dermatology.

[234]  B. Feldman,et al.  Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. , 2014, Journal of clinical epidemiology.

[235]  M. Kirschfink,et al.  Complement Profile in Neonates of Different Gestational Ages , 2014, Scandinavian journal of immunology.

[236]  H. Farkas,et al.  The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency , 2014, Orphanet Journal of Rare Diseases.

[237]  W. Aberer,et al.  Open‐label, multicenter study of self‐administered icatibant for attacks of hereditary angioedema , 2014, Allergy.

[238]  J. Bernstein,et al.  Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[239]  S. Fernando,et al.  Hereditary cause of severe recurrent bowel swelling that requires targeted therapy , 2014, The Medical journal of Australia.

[240]  T. Rossmanith,et al.  Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study , 2013, Transfusion.

[241]  B. Stahl,et al.  Outcome following tranexamic acid exposure during breastfeeding. , 2014, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

[242]  J. Bernstein,et al.  Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. , 2014, The journal of allergy and clinical immunology. In practice.

[243]  C. Verhoef,et al.  Hepatocellular carcinoma after danazol treatment for hereditary angio-oedema. , 2014, The Netherlands journal of medicine.

[244]  T. Renné,et al.  Bradykinin in health and disease: proceedings of the Bradykinin Symposium 2012, Berlin 23–24 August 2012 , 2014, Inflammation Research.

[245]  C. Hack,et al.  Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. , 2013, British journal of clinical pharmacology.

[246]  M. Frank.  Update on preventive therapy (prophylaxis) for hereditary angioedema. , 2013, Immunology and allergy clinics of North America.

[247]  T. Craig,et al.  Assessment of hereditary angioedema treatment risks. , 2013, Allergy and asthma proceedings.

[248]  A. Gompel,et al.  Hereditary angioedema in women: specific challenges. , 2013, Immunology and allergy clinics of North America.

[249]  M. Riedl.  Creating a comprehensive treatment plan for hereditary angioedema. , 2013, Immunology and allergy clinics of North America.

[250]  P. Martus,et al.  Development, validation, and initial results of the Angioedema Activity Score , 2013, Allergy.

[251]  T. Machnig,et al.  Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[252]  J. Bernstein,et al.  US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. , 2013, The journal of allergy and clinical immunology. In practice.

[253]  T. Klingebiel,et al.  Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history , 2013, Allergy.

[254]  J Dempster,et al.  In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency , 2013, Clinical and experimental immunology.

[255]  M. Magerl,et al.  Practical Approach to Self-Administration of Intravenous C1-INH Concentrate: A Nursing Perspective , 2013, International Archives of Allergy and Immunology.

[256]  W. Lumry,et al.  Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. , 2013, The Journal of pediatrics.

[257]  T. Craig,et al.  Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration , 2013, International Archives of Allergy and Immunology.

[258]  A. Gompel,et al.  Benefits of progestin contraception in non‐allergic angioedema , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[259]  H. Farkas,et al.  Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. , 2013, The Journal of allergy and clinical immunology.

[260]  T. Craig,et al.  Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. , 2013, Allergy and asthma proceedings.

[261]  A. Sheffer,et al.  Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[262]  W. Aberer,et al.  Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment , 2013, PloS one.

[263]  T. Klingebiel,et al.  Does Early Clinical Manifestation of Hereditary Angioedema (HAE) Influence the Clinical Course of the Disease , 2013 .

[264]  H. Farkas,et al.  Prophylactic therapy in children with hereditary angioedema. , 2013, The Journal of allergy and clinical immunology.

[265]  M. Cicardi,et al.  Diagnosing angioedema. , 2013, Immunology and allergy clinics of North America.

[266]  T. Caballero.  Angio-oedema due to hereditary C1 inhibitor deficiency in children. , 2013, Allergologia et immunopathologia.

[267]  M. Pedrosa,et al.  Management of dental-oral procedures in patients with hereditary angioedema due to C1 inhibitor deficiency. , 2013, Journal of investigational allergology & clinical immunology.

[268]  M. Mannesse,et al.  Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. , 2012, Journal of biotechnology.

[269]  H. Farkas,et al.  Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[270]  W. Aberer,et al.  International consensus on hereditary and acquired angioedema. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[271]  H. Farkas,et al.  Short‐term prophylaxis in hereditary angioedema due to deficiency of the C1‐inhibitor – a long‐term survey , 2012, Allergy.

[272]  R. Lockey,et al.  WAO Guideline for the Management of Hereditary Angioedema , 2012, The World Allergy Organization journal.

[273]  Adrian F Hernandez,et al.  Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. , 2012, Archives of internal medicine.

[274]  T. Nowak,et al.  Pathogen safety of human C1 esterase inhibitor concentrate , 2012, Transfusion.

[275]  P. Martus,et al.  Development and construct validation of the angioedema quality of life questionnaire , 2012, Allergy.

[276]  T. Machnig,et al.  Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks , 2012, Advances in Therapy.

[277]  A. Knulst,et al.  Clinical impact of peripheral attacks in hereditary angioedema patients. , 2012, The American journal of medicine.

[278]  B. Zuraw,et al.  Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. , 2012, The American journal of medicine.

[279]  K. Bork,et al.  Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. , 2012, The Journal of allergy and clinical immunology.

[280]  E. Remor,et al.  Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project , 2012, Health and Quality of Life Outcomes.

[281]  M. Frank.  Hereditary angioedema: short-term prophylaxis for surgery. , 2012, Allergy and asthma proceedings.

[282]  M. Abuzakouk,et al.  Danazol-Induced Hepatocellular Carcinoma in a Patient with Hereditary Angioedema , 2012, Journal of Gastrointestinal Cancer.

[283]  M. Triggiani,et al.  Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[284]  D. Meyer‐Olson,et al.  Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies , 2012, European Journal of Pediatrics.

[285]  A. Huitema,et al.  Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. , 2012, Clinical immunology.

[286]  Tom Bowen,et al.  International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. , 2012, The Journal of allergy and clinical immunology.

[287]  M. Triggiani,et al.  Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group , 2012, Allergy.

[288]  T. Klingebiel,et al.  Home therapy with intravenous human C1‐inhibitor in children and adolescents with hereditary angioedema , 2012, Transfusion.

[289]  J. Cronin,et al.  Treatment of an acute attack of type III hereditary angioedema with ecallantide. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[290]  T. Machnig,et al.  C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study , 2011, Allergy.

[291]  C. Town,et al.  Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[292]  J. Koziol,et al.  Safety and Efficacy of Physician-Supervised Self-Managed C1 Inhibitor Replacement Therapy , 2011, International Archives of Allergy and Immunology.

[293]  B. Zuraw,et al.  Pathophysiology of Hereditary Angioedema , 2011, American journal of rhinology & allergy.

[294]  P. Howarth,et al.  New topics in bradykinin research , 2011, Allergy.

[295]  M. López-Trascasa,et al.  SERPING1 mutations in 59 families with hereditary angioedema. , 2011, Molecular immunology.

[296]  D. Solé,et al.  Brazilian guidelines for the diagnosis and treatment of hereditary angioedema , 2011, Clinics.

[297]  T. Craig,et al.  Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. , 2011, Allergy and asthma proceedings.

[298]  A. Sheffer,et al.  Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. , 2011, The Journal of allergy and clinical immunology.

[299]  K. Bork,et al.  Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[300]  P. Bossuyt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations , 2011, Allergy.

[301]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[302]  H. Farkas,et al.  Long‐term efficacy of danazol treatment in hereditary angioedema , 2011, European journal of clinical investigation.

[303]  M. Cicardi,et al.  Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21‐month prospective study in a cohort of 103 patients , 2011, Allergy.

[304]  M. Maurer,et al.  Long‐term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[305]  M. López-Trascasa,et al.  Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. , 2011, Journal of investigational allergology & clinical immunology.

[306]  M. López-Trascasa,et al.  Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. , 2011, Journal of investigational allergology & clinical immunology.

[307]  M. Zilberberg,et al.  The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. , 2010, Allergy and asthma proceedings.

[308]  J. Bernstein,et al.  Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedema , 2010, Journal of cardiothoracic surgery.

[309]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[310]  H. Farkas,et al.  The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[311]  J. Bernstein,et al.  Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. , 2010, The New England journal of medicine.

[312]  A. Sheffer,et al.  Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.

[313]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[314]  J. Bernstein,et al.  Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[315]  T. Klingebiel,et al.  Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. , 2010, American journal of obstetrics and gynecology.

[316]  T. Bowen.  Hereditary Angioedema Consensus 2010 , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[317]  T. Klingebiel,et al.  On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[318]  P. Keith,et al.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[319]  H. Farkas.  Pediatric hereditary angioedema due to C1-inhibitor deficiency. , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[320]  M. Gompels,et al.  HAE international home therapy consensus document , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[321]  William H. Yang,et al.  Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema , 2010, Journal of Clinical Immunology.

[322]  W. Lumry,et al.  EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[323]  A. Neskovic,et al.  Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis. , 2010, Clinical therapeutics.

[324]  K. Bork,et al.  Economic costs associated with acute attacks and long-term management of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[325]  T. Klingebiel,et al.  Pharmacokinetic analysis of human plasma–derived pasteurized C1‐inhibitor concentrate in adults and children with hereditary angioedema: a prospective study , 2010, Transfusion.

[326]  H. Farkas,et al.  The effect of long-term danazol prophylaxis on liver function in hereditary angioedema—a longitudinal study , 2010, European Journal of Clinical Pharmacology.

[327]  A. Bygum,et al.  Hereditary angio‐oedema in Denmark: a nationwide survey , 2009, The British journal of dermatology.

[328]  J. Cesbron,et al.  Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[329]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[330]  T. Klingebiel,et al.  C1‐inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis , 2009, Transfusion.

[331]  B. Zuraw,et al.  Pathogenesis and laboratory diagnosis of hereditary angioedema. , 2009, Allergy and asthma proceedings.

[332]  K. Bork,et al.  Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. , 2009, The American journal of medicine.

[333]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines , 2009, Allergy.

[334]  H. Farkas,et al.  Disease expression in women with hereditary angioedema. , 2008, American journal of obstetrics and gynecology.

[335]  H. Joller-jemelka,et al.  Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. , 2008, Journal of immunological methods.

[336]  A. Tordai,et al.  Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. , 2008, Molecular immunology.

[337]  T. Craig.  Appraisal of danazol prophylaxis for hereditary angioedema. , 2008, Allergy and asthma proceedings.

[338]  P. Gorman.  Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate. , 2008, Canadian family physician Medecin de famille canadien.

[339]  K. Bork,et al.  Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[340]  William H. Yang,et al.  Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[341]  H. Farkas,et al.  Management of Hereditary Angioedema in Pediatric Patients , 2007, Pediatrics.

[342]  Yung-Yee Chang,et al.  Intracranial hypertension associated with danazol withdrawal: a case report. , 2007, Acta neurologica Taiwanica.

[343]  M. Tarzi,et al.  An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio‐oedema , 2007, Clinical and experimental immunology.

[344]  H. Farkas,et al.  Helicobacter pylori Infection as a Triggering Factor of Attacks in Patients with Hereditary Angioedema , 2007 .

[345]  H. Schuitemaker,et al.  Viral safety of C1-inhibitor NF. , 2007, Biologicals : journal of the International Association of Biological Standardization.

[346]  P. Schlattmann,et al.  Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.

[347]  M. Gulec,et al.  A successful pregnancy and uncomplicated labor with C1INH concentrate prophylaxis in a patient with hereditary angioedema. , 2007, Allergologia et immunopathologia.

[348]  K. Bork.  Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. , 2006, Immunology and allergy clinics of North America.

[349]  C. Weiler,et al.  Genetic test indications and interpretations in patients with hereditary angioedema. , 2006, Mayo Clinic proceedings.

[350]  D. Churchill,et al.  Pregnancy and C1 esterase inhibitor deficiency: a successful outcome , 2006, Archives of Gynecology and Obstetrics.

[351]  K. Bork,et al.  Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. , 2006, Biochemical and biophysical research communications.

[352]  K. Bork,et al.  Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.

[353]  A. Eckardt,et al.  Symptoms, Course, and Complications of Abdominal Attacks in Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2006, The American Journal of Gastroenterology.

[354]  A. Eerenberg,et al.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[355]  A. Kaplan,et al.  Continuing Medical EducationAngioedema , 2005 .

[356]  M. Tang,et al.  Hereditary angio‐oedema in children: A management guideline , 2005, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[357]  H. Longhurst.  Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? , 2005, International journal of clinical practice.

[358]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[359]  K. Kragballe,et al.  Hereditary Angioedema. , 2018, The New England journal of medicine.

[360]  William H. Yang,et al.  Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2004, The Journal of allergy and clinical immunology.

[361]  H. Griffiths,et al.  Normal complement C4 values do not exclude hereditary angioedema , 2004, Journal of Clinical Pathology.

[362]  R. Couture,et al.  Capillary permeability induced by intravenous neurokinins , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[363]  J. Stewart,et al.  Analysis of the receptors mediating vascular actions of bradykinin , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

[364]  E. Whalley,et al.  Analysis of the mechanism of action of bradykinin on human basilar artery in vitro , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

[365]  J. Lindner,et al.  Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: a review , 2003 .

[366]  B. Zuraw.  Diagnosis and management of hereditary angioedema: an American approach. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[367]  K. Bork,et al.  Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. , 2003, Journal of the American Dental Association.

[368]  G. Chrousos,et al.  Endocrine withdrawal syndromes. , 2003, Endocrine reviews.

[369]  K. Bork,et al.  Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. , 2003, Archives of internal medicine.

[370]  J. Lindner,et al.  Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[371]  M. Cicardi,et al.  Bradykinin-mediated angioedema. , 2002, The New England journal of medicine.

[372]  H. Farkas,et al.  Clinical management of hereditary angio‐oedema in children , 2002, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[373]  K. Bork,et al.  Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. , 2002, Journal of hepatology.

[374]  M. Silverberg,et al.  Pathways for bradykinin formation and inflammatory disease. , 2002, The Journal of allergy and clinical immunology.

[375]  K. Bork,et al.  Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. , 2001, Archives of internal medicine.

[376]  S. Choquet,et al.  Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. , 2000, The Journal of allergy and clinical immunology.

[377]  K. Binkley,et al.  Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. , 2000, The Journal of allergy and clinical immunology.

[378]  K. Bork,et al.  Hereditary angioedema with normal C1-inhibitor activity in women , 2000, The Lancet.

[379]  K. Bork,et al.  Asphyxiation by laryngeal edema in patients with hereditary angioedema. , 2000, Mayo Clinic proceedings.

[380]  N. Black,et al.  Consensus Development Methods: A Review of Best Practice in Creating Clinical Guidelines , 1999, Journal of health services research & policy.

[381]  H. Farkas,et al.  The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. , 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[382]  K. Bork,et al.  Hepatocellular adenomas in patients taking danazol for here ditary angiooedema , 1999, The Lancet.

[383]  M. Cicardi,et al.  Plasma bradykinin in angio-oedema , 1998, The Lancet.

[384]  F. Rosen,et al.  A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema , 1998, Transfusion.

[385]  A. Black,et al.  Angiotensin–converting enzyme (ACE) inhibitors and angio–oedema , 1997, The British journal of dermatology.

[386]  H. Galan,et al.  Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. , 1996, The Journal of reproductive medicine.

[387]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[388]  T. Mollnes,et al.  C1 Inhibitor and Diagnosis of Hereditary Angioedema in Newborns , 1994, Pediatric Research.

[389]  P. Brunskill.  The effects of fetal exposure to danazol , 1992, British journal of obstetrics and gynaecology.

[390]  T. Hedner,et al.  Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. , 1992, BMJ.

[391]  P. Brunskill.  The effects of fetal exposure to danazol , 1992 .

[392]  S. Leodolter,et al.  C1-Esterase Inhibitor in Uncomplicated Pregnancy and Mild and Moderate Preeclampsia , 1991, Thrombosis and Haemostasis.

[393]  Wellbutrin,et al.  Prescribing Information , 2015, European journal of haematology.

[394]  B. Wüthrich,et al.  Angioedema. A review on the acquired, allergic or non-allergic, and the hereditary forms. , 1990, Recenti progressi in medicina.

[395]  A. Kaplan,et al.  Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. , 1983, The Journal of allergy and clinical immunology.

[396]  F. Rosen,et al.  Kinin generation in hereditary angioneurotic edema (H.A.N.E.) plasma. , 1983, Advances in experimental medicine and biology.

[397]  M. Cicardi,et al.  Hereditary Angioedema: An Appraisal of 104 Cases , 1982, The American journal of the medical sciences.

[398]  A. C. Wentz.  Adverse effects of danazol in pregnancy. , 1982, Annals of internal medicine.

[399]  A. Sheffer,et al.  Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. , 1981, The Journal of allergy and clinical immunology.

[400]  D. Ogston,et al.  C1 inactivator level in pregnancy. , 1981, Thrombosis research.

[401]  M. Cicardi,et al.  Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. , 1980, The Journal of allergy and clinical immunology.

[402]  A. Sheffer,et al.  Methyltestosterone therapy in hereditary angioedema. , 1977, Annals of internal medicine.

[403]  Black Wp.  Danazol in the treatment of hereditary angio-neurotic oedema. , 1977 .

[404]  W. P. Blackmore.  Danazol in the treatment of hereditary angio-neurotic oedema. , 1977, The Journal of international medical research.

[405]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[406]  B. Zweiman,et al.  Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. , 1976, Blood.

[407]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[408]  F. Kueppers,et al.  Half‐life of CINH in hereditary angioneurotic oedema (HAE) * , 1975, Clinical allergy.

[409]  C. Gwynn.  Therapy in hereditary angioneurotic oedema , 1974, Archives of disease in childhood.

[410]  Schulz Kh.  [Hereditary Quincke's edema. New therapeutic ways]. , 1974 .

[411]  K. Schulz.  [Hereditary Quincke's edema. New therapeutic ways]. , 1974, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[412]  B. Lundh.  Tranexamic acid in hereditary angioneurotic edema--a progress report. , 1973, The New England journal of medicine.

[413]  V. Donaldson.  Kinin formation in hereditary angioneurotic edema (HANE) plasma. , 1973, International archives of allergy and applied immunology.

[414]  G. Blohmé.  Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. , 2009 .

[415]  P. Schur,et al.  Acquired C1 inhibitor deficiency in lymphosarcoma , 1972 .

[416]  A. Sheffer,et al.  Tranexamic acid therapy in hereditary angioneurotic edema. , 1972, The New England journal of medicine.

[417]  Norman Crolee Dalkey,et al.  An experimental study of group opinion , 1969 .

[418]  F. Rosen,et al.  The "neurotic edema" (hereditary angioedema). , 1969, The New England journal of medicine.

[419]  T. White,et al.  A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. , 1968, Clinical and experimental immunology.

[420]  F. Rosen,et al.  Hereditary Angioneurotic Edema: Two Genetic Variants , 1965, Science.

[421]  Uno Eriksoni.  Peripheral Arteriography during Bradykinin Induced Vasodilation , 1965 .

[422]  F. Rosen,et al.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE. , 1964, The Journal of clinical investigation.

[423]  R. R. Evans,et al.  A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. , 1963, The American journal of medicine.

[424]  M. Rocha e Silva,et al.  Coronary Vasodilation Produced by Bradykinin on Isolated Mammalian Heart , 1962, Circulation research.

[425]  M. Rocha e Silva,et al.  Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. , 1949, The American journal of physiology.

[426]  E. Dinkelacker.  Ueber acutes Oedem , 1882 .